Literature DB >> 9407969

Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma.

S J Hughes1, Y Nambu, O S Soldes, D Hamstra, A Rehemtulla, M D Iannettoni, M B Orringer, D G Beer.   

Abstract

This study describes Fas (CD95) expression in Barrett's esophagus, adenocarcinomas of the esophagus, and three esophageal adenocarcinoma cell lines. Immunohistochemical analysis of Barrett's esophagus demonstrated cell surface expression of Fas protein. In contrast, 30.5% of esophageal adenocarcinomas examined by immunohistochemical analysis demonstrated faint cytoplasmic staining, and 69.5% were negative for Fas. Similar levels of Fas mRNA were identified in tumors compared to mRNA levels in esophageal squamous mucosa or Barrett's esophagus. An approximately Mr 48,000 Fas protein was identified by Western blot analysis in tumors that were negative for Fas expression by immunohistochemical analysis. The esophageal adenocarcinoma cell line Seg-1 was negative for Fas expression by immunohistochemical analysis, but Western blot analysis demonstrated abundant, appropriately sized Fas protein. In agreement with the immunohistochemical analysis, flow cytometry of Seg-1 showed minimal amounts of Fas on the cell surface, which correlated with resistance to Fas-mediated apoptosis. No mutations in the Seg-1 Fas coding sequence or exon 1 were identified by sequence analysis. This was confirmed by transient transfection of COS cells with expression vectors generated from the Seg-1 Fas cDNA, which resulted in cell surface expression of the Fas protein. Stable transfection of Seg-1 with a Fas expression vector did not result in efficient Fas expression on the cell surface. Seg-1 cells, transiently transfected with a Fas-FLAG expression vector and examined for protein expression using confocal microscopy and an anti-FLAG antibody, showed that the Fas-FLAG protein was not present on the cell surface but was present in the cytoplasm. Taken together, these results indicate that expression of Fas on the cell surface by esophageal adenocarcinoma is reduced. In an esophageal adenocarcinoma cell line, wild-type Fas protein is retained in the cytoplasm, and this correlates with resistance to Fas-mediated apoptosis. The retention of wild-type Fas protein within the cytoplasm may represent a mechanism by which malignant cells evade Fas-mediated apoptosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407969

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia.

Authors:  S J Hughes; M A Morse; C M Weghorst; H Kim; P B Watkins; F P Guengerich; M B Orringer; D G Beer
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

Review 3.  Barrett's esophagus: environmental influences in the progression of dysplasia.

Authors:  Ralph A Boulton; Bernhard Usselmann; Imtiyaz Mohammed; Janusz Jankowski
Journal:  World J Surg       Date:  2003-07-28       Impact factor: 3.352

Review 4.  Risk factors for neoplastic progression in Barrett's esophagus.

Authors:  Elizabeth F Wiseman; Yeng S Ang
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

Review 5.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

6.  Role of NADPH oxidase NOX5-S, NF-κB, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells.

Authors:  Jie Hong; Dan Li; Jack Wands; Rhonda Souza; Weibiao Cao
Journal:  Am J Physiol Cell Physiol       Date:  2013-09-11       Impact factor: 4.249

7.  Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.

Authors:  Amy L Silvers; Lin Lin; Adam J Bass; Guoan Chen; Zhuwen Wang; Dafydd G Thomas; Jules Lin; Thomas J Giordano; Mark B Orringer; David G Beer; Andrew C Chang
Journal:  Clin Cancer Res       Date:  2010-03-23       Impact factor: 12.531

8.  The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma.

Authors:  Luis J Herrera; Talal El-Hefnawy; Pierre E Queiroz de Oliveira; Siva Raja; Sydney Finkelstein; William Gooding; James D Luketich; Tony E Godfrey; Steven J Hughes
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

9.  Silencer-of-Death Domain Mediates Acid-Induced Decrease in Cell Apoptosis in Barrett's Associated Esophageal Adenocarcinoma Cells.

Authors:  Dan Li; Jie Hong; Weibiao Cao
Journal:  J Pharmacol Exp Ther       Date:  2016-10-18       Impact factor: 4.030

10.  Bile acid reflux contributes to development of esophageal adenocarcinoma via activation of phosphatidylinositol-specific phospholipase Cgamma2 and NADPH oxidase NOX5-S.

Authors:  Jie Hong; Jose Behar; Jack Wands; Murray Resnick; Li Juan Wang; Ronald A Delellis; David Lambeth; Weibiao Cao
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.